• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Hikma to acquire the EPCI in Egypt

Hikma to acquire the EPCI in Egypt

January 11, 2013
CenterWatch Staff

Hikma Pharmaceuticals, a multinational pharmaceutical group, has agreed to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI) from a consortium of shareholders for an aggregate cash consideration of approximately $22.2 million.

The acquisition strengthens Hikma's position in the large and fast growing Egyptian market and adds a complementary portfolio of 35 products in 46 dosage forms and strengths, including three original cephalosporin anti–infective brands for the Egyptian market. The acquisition also adds a dedicated cephalosporin facility and an additional general formulation manufacturing plant in Egypt.

"Since we entered the Egyptian market in 2007, we have been rapidly growing our presence. This acquisition will further accelerate that growth, expanding our product portfolio and adding additional manufacturing capacity and technologies,” said Said Darwazah, CEO of Hikma. “We continue to strengthen our position as the leading regional manufacturer in MENA and to pursue other value–creating acquisition opportunities in the region."

The Egyptian pharmaceutical market is one of the largest and fastest growing MENA markets. According to IMS Health, the private retail market is valued at around $2.3 billion and grew by 10.6% in the 12 months prior to June 2012. Hikma Egypt is currently the seventeenth largest pharmaceutical manufacturer in Egypt, with an estimated market share of 1.6%.

Closing is expected to occur before February 14, 2013, and is conditional on fulfillment of conditions precedent.

HC Securities and Investment, the Cairo–based investment bank, acted as advisor to Hikma on this acquisition.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing